Citizens Capital Markets Maintains Market Outperform on Neuronetics, Raises Price Target to $7
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Citizens Capital Markets analyst Daniel Stauder maintains Neuronetics (NASDAQ:STIM) with a Market Outperform and raises the price target from $3 to $7.
Citizens Capital Markets analyst Daniel Stauder maintains Neuronetics (NASDAQ:STIM) with a Market Outperform and raises the price target from $3 to $7.